- Home
- CNFR vs ACXP Comparison
CNFR vs ACXP Comparison
Compare CNFR & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNFR
- ACXP
- Stock Information
- Founded
- CNFR 2009
- ACXP 2017
- Country
- CNFR United States
- ACXP United States
- Employees
- CNFR N/A
- ACXP N/A
- Industry
- CNFR Property-Casualty Insurers
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- CNFR Finance
- ACXP Health Care
- Exchange
- CNFR Nasdaq
- ACXP Nasdaq
- Market Cap
- CNFR 7.9M
- ACXP 8.4M
- IPO Year
- CNFR 2015
- ACXP 2021
- Fundamental
- Price
- CNFR $0.76
- ACXP $0.35
- Analyst Decision
- CNFR
- ACXP Strong Buy
- Analyst Count
- CNFR 0
- ACXP 2
- Target Price
- CNFR N/A
- ACXP $10.00
- AVG Volume (30 Days)
- CNFR 11.1K
- ACXP 235.0K
- Earning Date
- CNFR 05-14-2025
- ACXP 05-13-2025
- Dividend Yield
- CNFR N/A
- ACXP N/A
- EPS Growth
- CNFR N/A
- ACXP N/A
- EPS
- CNFR 1.96
- ACXP N/A
- Revenue
- CNFR $64,021,000.00
- ACXP N/A
- Revenue This Year
- CNFR $25.91
- ACXP N/A
- Revenue Next Year
- CNFR N/A
- ACXP N/A
- P/E Ratio
- CNFR $0.38
- ACXP N/A
- Revenue Growth
- CNFR N/A
- ACXP N/A
- 52 Week Low
- CNFR $0.42
- ACXP $0.30
- 52 Week High
- CNFR $1.91
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- CNFR 47.88
- ACXP 37.87
- Support Level
- CNFR $0.75
- ACXP $0.34
- Resistance Level
- CNFR $0.85
- ACXP $0.36
- Average True Range (ATR)
- CNFR 0.03
- ACXP 0.02
- MACD
- CNFR -0.01
- ACXP -0.00
- Stochastic Oscillator
- CNFR 18.85
- ACXP 5.19
About CNFR Conifer Holdings Inc.
Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.